Cover Image
市場調查報告書

注射型藥物輸送設備的全球市場的未來預測

Injectable Drug Delivery Market: By Devices (Auto Drug Injecting, Pen Injectors, Others); By Drug Formulations (Conventional, Novel ); By Therapeutic Area (Hormonal Disorders, Oncology, Auto-Immune, Others); By Geography - (2010-2018)

出版商 IndustryARC 商品編碼 622518
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
注射型藥物輸送設備的全球市場的未來預測 Injectable Drug Delivery Market: By Devices (Auto Drug Injecting, Pen Injectors, Others); By Drug Formulations (Conventional, Novel ); By Therapeutic Area (Hormonal Disorders, Oncology, Auto-Immune, Others); By Geography - (2010-2018)
出版日期: 2017年08月17日 內容資訊: 英文 165 Pages
簡介

本報告提供全球注射型藥物輸送設備的市場相關分析,提供整體市場結構和背景情況,主要的推動及阻礙市場要素,各產品種類 (設備,劑型)·各疾病·各地區的市場趨勢預測,市場競爭情勢,近來的資本交易·策略發展的動向,主要企業的簡介等相關調查。

第1章 市場概要

第2章 摘要整理

第3章 市場環境

  • 市場佔有率分析
  • 比較分析
    • 產品的互相比較
    • 終端用戶的簡介
    • 專利分析
    • 前五名公司的財務分析

第4章 全球注射式藥物輸送設備市場:對市場的影響要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場課題
  • 市場向心力:波特的五力分析

第5章 全球注射式藥物輸送設備市場:策略分析

  • 價值鏈分析
  • 市場機會分析
  • 產品/市場生命週期分析

第6章 全球注射式藥物輸送設備市場:各類型

  • 醫藥品的劑型方法
  • 不同設備
    • 傳統的設備
    • 自動注射設備
    • 自行注射設備
    • 筆型注射器
    • 無針頭注射設備
  • 其他

第7章 全球注射式藥物輸送設備市場:疾病類別

  • 貧血症
  • 糖尿病
  • 多發性硬化症
  • 風濕
  • 克隆氏症
  • 其他

第8章 全球注射式藥物輸送設備市場:各地區

  • 簡介
  • 北美 (加拿大,海地,墨西哥,美國等)
  • 中南美 (阿根廷,巴西,智利,哥倫比亞,委內瑞拉等)
  • 歐洲 (德國,法國,義大利,俄羅斯,西班牙,土耳其,英國等)
  • 亞太地區 (孟加拉,中國,印度,尼泊爾,斯里蘭卡,新加坡,馬來西亞等)
  • 其他的國? (RoW)

第9章 市場熵 (市場變化的方向性)

  • 新產品的銷售
  • 企業合併·收購 (M&A),事業聯盟·合作,合資企業 (JV)

第10章 企業簡介 (概要,財務分析,SWOT分析,近幾年趨勢,產品系列)

  • Becton Dickinson and Company (BD)
  • Baxter International Inc.
  • Consort Medical PLC
  • Crossject SA
  • Eli Lilly and Company
  • Elcam Medical
  • Novo Nordisk
  • Owen Mumford Ltd
  • Sanofi
  • Schott AG
  • Terumo Corporation
  • Ypsomed Holding AG
  • 其他

第11章 附錄

目錄

The Global Injectable Drug Delivery Devices Market has been analyzed with respect to the demand for devices from different countries across the globe. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2020. The drug injection devices market has been segmented into conventional injectors and self-injection devices broadly. Similarly the drug formulations market has been segmented into the conventional drugs and novel drugs segments. The therapeutic areas are further segmented and analyzed in this report.

While conventional devices are growing at a CAGR of 7.37%, self-injection devices are expected to grow at 16.6% during 2013 - 2018. Conventional injection devices hold around 87% market share currently but this is expected to decrease to around 83% by 2018, as the use of self-injection devices increases in the next 5 years.

The global injectable drug delivery devices market is expected to increase from around $ 11.6 bn in 2013 to around $ 17.5 bn in 2018. Self-injection devices are expected to grow at the highest growth rate of 16.1% with conventional injection devices growing at only 7.4% during the forecast period 2013 - 2018.

Analyzing the competitive landscape of the global conventional injectable devices market for 2012 IndustryARC is of the opinion that Becton Dickinson & Co. had the top position with a market share of around 27% followed by Baxter International Inc with a share of 23%. Overall these two companies along with Terumo Corporation and Schott AG together held market share of around 85%.

1. Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End user profiling
    • 3.2.3. Patent Analysis
    • 3.2.4. Top 5 Financials Analysis

4. Global Injectable Drug Delivery - Market Forces

  • 4.1. Market Drivers
    • 4.1.1. Inherent Use Case Scenario of IDD Devices With Biologics
    • 4.1.2. Increase in Global Diabetic Population and Usage of Insulin Pens
    • 4.1.3. Others
  • 4.2. Market Constraints
    • 4.2.1. Infection Risks And Government Laws
    • 4.2.2. Others
  • 4.3. Market Challenges
    • 4.3.1. Higher Manufacturing Standards Needed to Avoid Product Recalls
    • 4.3.2. Others
  • 4.4. Attractiveness of the Industry
    • 4.4.1. Power of Suppliers
    • 4.4.2. Power of Customers
    • 4.4.3. Threat of New entrants
    • 4.4.4. Threat of Substitution
    • 4.4.5. Degree of Competition

5. Global Injectable Drug Delivery Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Opportunities Analysis
  • 5.3. Product/Market Life Cycle Analysis

6. Global Injectable Drug Delivery Market - By Type

  • 6.1. Pharmaceutical Drug Formulations
  • 6.2. By Device
    • 6.2.1. Conventional Devices
    • 6.2.2. Auto Injector Devices
    • 6.2.3. Self Injector Devices
    • 6.2.4. Pen Injectors
    • 6.2.5. Needle Free Injector Devices
  • 6.3. Others

7. Global Injectable Drug Delivery Market - By Type of Diseases

  • 7.1. Anemia
  • 7.2. Diabetes
  • 7.3. Multiple sclerosis
  • 7.4. Rheumatoid
  • 7.5. Crohn's
  • 7.6. Others

8. Global Injectable Drug Delivery Market -Geographic Analysis

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. Canada
    • 8.2.2. Haiti
    • 8.2.3. Mexico
    • 8.2.4. USA
    • 8.2.5. Others
  • 8.3. South & Central America
    • 8.3.1. Argentina
    • 8.3.2. Brazil
    • 8.3.3. Chile
    • 8.3.4. Colombia
    • 8.3.5. Venezuela
    • 8.3.6. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. Italy
    • 8.4.4. Russia
    • 8.4.5. Spain
    • 8.4.6. Turkey
    • 8.4.7. U.K
    • 8.4.8. Others
  • 8.5. APAC
    • 8.5.1. Bangladesh
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Nepal
    • 8.5.5. Srilanka
    • 8.5.6. Singapore
    • 8.5.7. Malaysia
    • 8.5.8. Others
  • 8.6. ROW

9. Market Entropy

  • 9.1. New Product Launches
  • 9.2. M&As, Collaborations, JVs and Partnerships

10. Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolio)

  • 10.1. Becton Dickinson and Company (BD)
  • 10.2. Baxter International Inc.
  • 10.3. Consort Medical PLC
  • 10.4. Crossject SA
  • 10.5. Eli Lilly and Company
  • 10.6. Elcam Medical
  • 10.7. Novo Nordisk
  • 10.8. Owen Mumford Ltd
  • 10.9. Sanofi
  • 10.10. Schott AG
  • 10.11. Terumo Corporation
  • 10.12. Ypsomed Holding AG
  • 10.13. Others

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top